SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.
SciRhom has raised $68.1M in total funding. The most recent round was Series A. The last funding was announced in July 2024.
SciRhom's investors include HTGF (High-Tech Gruenderfonds), Kurma Partners, Wellington Partners, Hospital for Special Surgery, Andera Partners.
SciRhom is headquartered in Martinsried, Germany.
SciRhom is a biotech enterprise that translate advanced scientific findings into game-changing therapies for autoimmune diseases.
SciRhom is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SciRhom — Funding & Investors." VCBacked, July 9, 2024, https://www.vcbacked.co/company/scirhom. Accessed August 1, 2026.
VCBacked. (2024). SciRhom — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/scirhom
{{cite web |title=SciRhom — Funding & Investors |url=https://www.vcbacked.co/company/scirhom |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated